Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study

Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no approved drugs are available for treatment, according to a press release from Durect Corporation.
Durect announced positive data from a phase 1b trial of orally administered DUR-928 in NASH that demonstrated significant improvement in liver function. DUR-928 is reportedly the first endogenous epigenetic regulator that was clinically tested for difficult-to-treat liver diseases.
Healio Gastroenterology spoke with Eric Lawitz, MD, from the Texas Liver

Source link

Related posts

5 Things You Should Know About Hereditary Colon Cancer


First incidence and associated factors of overweight and obesity from preschool to primary school: longitudinal analysis of a national cohort in Japan


AGA does not recommend probiotics for most GI conditions


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World